Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study

Abstract

The PROMO (preference for once monthly bisphosphonate) Study, conducted in seven hospital centres in Croatia between June 2007 and June 2008, was designed to analyse patient preference for weekly and monthly bisphosphonates in everyday clinical practice where the significant proportion of patients are not completely satisfied with the current osteoporosis treatment. Eligible participants were women with postmenopausal osteoporosis taking weekly bisphosphonates for the last 6 months. Those who agreed to be enrolled were transferred from weekly to monthly ibandronate for the next 6 months. There was no washout period between the two treatment regimens. At the baseline, patients expressed their satisfaction with the weekly treatment. At the end of the study, all patients were asked to complete the five-question survey specially designed for this study. Study population comprised 258 participants. Among 248 patients who completed the study, 244 (98.4%) declared their preference for one of the regimens or they had no preference. Once-monthly regimen was preferred by 231 patients (94.7%), whereas once-weekly regimen was preferred by five patients (2.0%). Eight patients (3.3%) indicated no preference. Furthermore, 93.0% of patients thought that monthly dosing was more convenient. Compared to weekly regimen, monthly dosing was associated with significantly higher satisfaction with the treatment and with significantly less adverse events. In line with these data, 85.9% of patients stated improved quality of life with monthly ibandronate. In summary, the PROMO Study demonstrated strong patient preference for monthly over weekly dosing which is expected to improve suboptimal adherence to weekly bisphosphonates.

Health-Related Quality of Life Among Patients with Postmenopausal Osteoporosis Treated with Weekly and Monthly Bisphosphonates

“…There is a strong evidence that monthly ibandronate is preferred by patients over weekly bisphosphonates (14)(15)(16)21). Similarly, a majority of patients stated that a monthly dosing regimen is more convenient and better fitted to their lifestyle.…”

“…Similarly, a majority of patients stated that a monthly dosing regimen is more convenient and better fitted to their lifestyle. Moreover, several studies reported significantly lower incidence of adverse events associated with monthly compared to weekly bisphosphonates (14,24).…”

“…Several studies reported improved adherence with reducing bisphosphonate dosing frequency (12,13). Moreover, data has shown that less frequent dosing is more convenient for the patient (14)(15)(16).…”

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

“…Most previous studies of bisphosphonate treatment preference and adherence have either used non-interventional designs [13,24,27], or they have been randomized studies that included questions about treatment preference but not about adherence [28][29][30][31][32]. Few studies have prospectively evaluated bisphosphonate treatment adherence [33,34].…”

Günlük veya Haftalık Alendronat veya Risendronat Alan Postmenopozal Osteoporozlu Kadınlarda Aylık İbandronat İçin Hasta Tercihinin Değerlendirildiği Açık-Etiketli, Prospektif, Çok-Merkezi, İki-Aşamalı Çalışma-BONCURE: Türkiye Alt-Çalışması

“…The MOBILE study showed that monthly oral administration of 100 mg and 150 mg ibandronate regimens were as effective as 2.5 mg daily oral ibandronate and well tolerated (17,18). In the recent studies, patients previously using weekly bisphosphonates (alendronate) reported improved satisfaction and preference with monthly ibandronate dosing (19)(20)(21). To collect further regional data on preference of patients for different dosing regimens of bisphosphonates, BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial) study evaluated the patients' satisfaction, preference and compliance, and tolerability of monthly ibandronate 150 mg in women with postmenopausal osteoporosis who had previously received weekly or daily alendronate or risedronate by using a validated satisfaction instrument relevant to treatment for osteoporosis (Osteoporosis Patient Satisfaction Questionnaire, OPSAT-Q).…”